CAMBRIDGE, Mass., May 29, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced the recent publication of a new scientific paper further supporting Hedgehog signaling pathway inhibition as a promising new approach to treat cancer. The data featured in the paper show that IPI-926, when administered in combination with gemcitabine in a preclinical mouse model of treatment-resistant pancreatic cancer, increased tumor cell death, resulting in a reduction of tumor size and increased survival. These data suggest that IPI-926 may enable chemotherapeutic agents to successfully access and kill tumor cells. Infinity is currently evaluating IPI-926 in a Phase 1 clinical trial in patients with advanced solid tumors.
